Planet MicroCap Las Vegas 2026
Logotype for Paysign Inc

Paysign (PAYS) Planet MicroCap Las Vegas 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Paysign Inc

Planet MicroCap Las Vegas 2026 summary

17 Jun, 2026

Financial Performance and Growth

  • Achieved $82 million in FY2025 revenue, up 40.5% year-over-year, with adjusted EBITDA of $19.9 million, a 107% increase and gross margin at 59.4%.

  • Patient affordability business grew 116.9% to $40.9 million, now representing 41.3% of total revenue, up from 21.7% in 2024.

  • Plasma revenue was $45.6 million in FY2025, up 4.0% YoY, with mature recurring revenue.

  • Guidance for FY2026 projects $106.5–$110.5 million in revenue and $30–$33 million in adjusted EBITDA, with a roughly equal split between plasma and patient affordability.

  • Operating leverage is expanding, with SG&A as a percentage of revenue declining and EBITDA margin expected to reach ~29% in FY2026.

Business Model, Operations, and Technology

  • Operates a unified payments platform serving both plasma donor compensation and pharma patient affordability, leveraging a fixed infrastructure for scalable growth.

  • Holds approximately 45.5% share of the U.S. plasma payments market, serving 554 facilities and 8.4 million cardholders as of May 2026.

  • Proprietary Dynamic Business Rules technology delivers 97% first-fill detection accuracy, saving clients over $325 million in 2025 by preventing fraudulent copay claims.

  • Apherion platform offers modular, cloud-based solutions for donor engagement, CRM, compensation, and compliance, consolidating legacy point solutions.

  • Revenue models are variable and usage-based, including per-donation transactions, software subscriptions, and recurring management fees.

Market Opportunity and Outlook

  • Plasma payments market estimated at $110 million; patient affordability at $500–$750 million.

  • Plasma and blood center software market projected to grow from $3.5 billion to $7.5 billion in 10 years.

  • Both plasma and patient affordability markets are structurally growing, with significant runway for expansion in the U.S. and potential international opportunities.

  • Added 55 new programs in 2024 and expects to add 60 in 2025, with average revenue per program rising.

  • Investments in technology and operations are now yielding significant returns.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more